Medtronic (NYSE:MDT) Upgraded at Mizuho

Mizuho upgraded shares of Medtronic (NYSE:MDT) to a strong-buy rating in a report released on Wednesday morning,Zacks.com reports.

Other analysts have also recently issued reports about the stock. TD Cowen reissued a “buy” rating on shares of Medtronic in a research note on Friday, November 14th. Barclays reiterated an “overweight” rating and issued a $118.00 price objective on shares of Medtronic in a research report on Wednesday. UBS Group reissued a “neutral” rating and issued a $104.00 target price on shares of Medtronic in a research note on Wednesday, February 4th. Truist Financial cut their price target on Medtronic from $110.00 to $107.00 and set a “hold” rating on the stock in a research note on Thursday, December 18th. Finally, Royal Bank Of Canada lifted their price objective on Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, Medtronic presently has an average rating of “Moderate Buy” and an average target price of $111.05.

Medtronic Price Performance

Shares of MDT stock opened at $96.88 on Wednesday. Medtronic has a 52 week low of $79.55 and a 52 week high of $106.33. The stock has a market capitalization of $124.20 billion, a PE ratio of 26.99, a PEG ratio of 2.45 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The stock’s fifty day moving average is $99.04 and its 200-day moving average is $96.65.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.88% and a net margin of 13.00%.The business had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. During the same period in the previous year, the business posted $1.38 earnings per share. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts expect that Medtronic will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date was Friday, December 26th. Medtronic’s dividend payout ratio is currently 79.11%.

Hedge Funds Weigh In On Medtronic

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Delos Wealth Advisors LLC bought a new position in Medtronic during the 2nd quarter worth approximately $27,000. Corundum Trust Company INC acquired a new stake in Medtronic in the third quarter worth $27,000. Lodestone Wealth Management LLC acquired a new stake in Medtronic in the fourth quarter worth $27,000. Anfield Capital Management LLC boosted its position in shares of Medtronic by 410.7% during the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 230 shares in the last quarter. Finally, Valley Wealth Managers Inc. acquired a new position in shares of Medtronic in the 3rd quarter valued at $29,000. Institutional investors own 82.06% of the company’s stock.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Regulatory/coverage win in Japan for Medtronic’s Symplicity Spyral renal denervation device and management commentary that the company is investing in rollout and hiring to support market development — supports revenue upside from a growing hypertension therapy. Medtronic’s blood pressure device wins coverage nod in Japan
• Positive Sentiment: Analyst upgrade: Mizuho moved Medtronic to a “strong-buy,” which can support buying interest and short-term momentum. Mizuho upgrade reported via Zacks
• Neutral Sentiment: Industry growth tailwinds — a separate report highlights expansion in non‑invasive therapies (HIFU) and robotics/image‑guided systems; positive for device sector demand but not a direct Medtronic headline. HIFU Market Competitive Landscape Report 2025
• Neutral Sentiment: Competitive update — Intuitive Surgical (ISRG) reports faster international procedure growth, which underscores competitive dynamics in robotics and could pressure Medtronic’s robotics expectations over time. ISRG’s International Growth Outpaces US
• Neutral Sentiment: Company commentary and Q3 earnings materials are out (transcript available) showing mixed results: solid robotics wins but offset by some legal and expense items — provides context for guidance and valuation debate. Medtronic (MDT) Q3 2026 Earnings Call Transcript
• Negative Sentiment: Multiple broker notes lowered expectations or targets (JPMorgan, Robert W. Baird; Leerink cut its target to $119) — analyst downgrades/target cuts weigh on sentiment and can amplify selling. JPMorgan low expectations
• Negative Sentiment: Planned layoffs: Medtronic will cut 81 roles at a California diabetes site as it readies the diabetes spin‑out; restructuring adds near‑term execution risk and uncertainty around the separations. Medtronic to cut 81 employees at California diabetes site
• Negative Sentiment: Broader skepticism in media pieces discussing mixed quarterly results, legal exposure and whether recent wins materially change Medtronic’s investment case — fuels analyst disagreement and investor caution. Mixed Q3 Results, Robotics Win and Legal Hit

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).